MedTrace Logo

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

NCT06336291 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-21

No results posted yet for this study

Summary

The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence

Conditions

Interventions

DRUG

L19TNF

7 μg/kg

DRUG

L19TNF

10 μg/kg

DRUG

L19TNF

13 μg/kg

DRUG

Lomustine

90 mg/m2

DRUG

Lomustine

110 mg/m2

Sponsors & Collaborators

  • Philogen S.p.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-22
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06336291 on ClinicalTrials.gov